In: NEOPLASMA, vol. 53, no. 5
R. Soumarová - L. Homola - M. Štursa - H. Perková
Detaily:
Rok, strany: 2006, 410 - 417
O článku:
Over the past few years, brachytherapy has become more and more
common in the treatment of prostate cancer, largely
thanks to the reduced amount of acute and chronic side effects. At
the same time, brachytherapy also allows dose escalation,
resulting in significant improvements in the treatment results.
From August 2004 to June 2005, we irradiated 40 patients suffering
from T1c—T3a prostate cancer. All of the patients underwent
external beam radiotherapy with a median dose of 45—50.4 Gy and a
conformal high dose interstitial brachytherapy
boost (two fractions, 8 Gy per fraction). The patients were
divided into three groups: low risk of recurrence (11 patients —
27.5%), intermediate risk (14 patients — 35%) and high risk (15
patients — 37.5%). The medium age of the patients was 68.7
years (between 55 and 77). Hormonal treatment was carried out 17
patients (42.5%). We evaluated the quality of each implantation,
including the maximum urethral and rectal dose. The calculated
doses were compared with measurements by in
vivo dosimetry. Acute toxicity was evaluated in all of the
patients according to the Radiation Therapy Oncology Group
(RTOG) scale. Each of the patients completed an International
Prostatic Symptom Score (IPSS) questionnaire.
Acute genitourinary morbidity grade 1 was recorded in 37.5% of
patients; grade 2 in 15% of patients. Urine retention in
one of the patients resulted in the need to perform an
epicystostomy. According to the IPSS score, the majority of
patients
(90%) experienced an improvement in symptoms related to quality of
life. Grade 1 acute gastrointestinal toxicity was recorded
in 40% of the patients. Grades 2—4 were not recorded.
Here, we show that the combination of external beam radiotherapy
and high dose rate (HDR) brachytherapy in the treatment
of early prostate cancer to be feasible and well tolerated. Acute
toxicity was low and scarcely influenced the quality of
life. Among the risk factors of genitourinary toxicity was the
volume of the prostate. For gastrointestinal toxicity, risk factors
included the combination of HDR brachytherapy and external beam
radiotherapy to the pelvis, as well as hormonal
treatment.
Ako citovať:
ISO 690:
Soumarová, R., Homola, L., Štursa, M., Perková, H. 2006. Acute toxicity of conformal high dose interstitial brachytherapy
boost in prostate cancer. In NEOPLASMA, vol. 53, no.5, pp. 410-417. 0028-2685.
APA:
Soumarová, R., Homola, L., Štursa, M., Perková, H. (2006). Acute toxicity of conformal high dose interstitial brachytherapy
boost in prostate cancer. NEOPLASMA, 53(5), 410-417. 0028-2685.